Update on Current and Future Management for Diabetic Maculopathy.

Fecha de publicación: 01/04/2022 Fecha Ahead of Print: 31/01/2022

Autores de IIS La Fe

• Patricia Udaondo Mirete

  Autor

Participantes ajenos a IIS La Fe

• Parravano, Mariacristina
• Vujosevic, Stela
• Zur, Dinah
• Chakravarthy, Usha

Grupos

• Biomedicina Molecular, Celular y Genómica

  

  Leader

  José María Millán Salvador

Abstract

Diabetic macular edema (DME) remains the major cause of preventable blindness in the working-age population in developed countries, and screening programs are extremely important in the management of this complication of diabetic retinopathy. The introduction of modern imaging modalities and technological advances have facilitated both the early detection and the follow-up of patients with DME, particularly optical coherence tomography angiography and artificial intelligence. Intravitreal therapy is the gold standard treatment for DME, but not all patients respond equally to this therapy, and sometimes it is not easy to apply treatment protocols correctly; for these reasons, clinical practice results may differ from those of clinical trials in terms of vision gain. One approach has been to implement new treatment regimens, such as treat and extend, and new molecules and therapeutic targets are constantly being developed. The main goal of this review paper is to describe the current treatment options and management strategies for DME in Europe and to provide a brief oversight of the novel therapeutic options on the horizon.

© 2022. The Author(s).

Keywords

• AntiVEGF; Diabetic macular edema; Diabetic retinopathy; Intravitreal therapy; Steroids